A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

It reduces transmissions by up to 96%, but now world governments and big-dollar funders will need to step in.

The LGBTQIA+ community and supporters participated in this year’s Honolulu AIDS Walk on Saturday to raise awareness about the ...

Funding uncertainty looms over lenacapavir for low-income countries despite FDA approval hopes Global Fund aims to raise $18 billion amid PEPFAR funding doubts Lenacapavir pricing crucial for ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Wednesday's approval marks the first step in an anticipated global rollout that experts say could protect millions.

World leaders are dismantling global health programs and cutting back foreign aid. Will an extraordinary new medicine be able ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...